financetom
Business
financetom
/
Business
/
Preformed Line Products' Q3 sales up on strong performance in energy market
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Preformed Line Products' Q3 sales up on strong performance in energy market
Oct 29, 2025 2:26 PM

Overview

* Preformed Line Products ( PLPC ) Q3 net sales rise 21% yr/yr, driven by energy and communication markets

* Adjusted EPS for Q3 rises 36% yr/yr, excluding pension termination charge

* Company completes U.S. Pension Plan termination, incurring $11.7 mln non-cash charge

Outlook

* Company expects selling price increases to eventually offset tariff-related cost impacts

* Company sees uncertainty in customer demand due to tariffs

Result Drivers

* ENERGY AND COMMUNICATION SALES - Strong performance in energy and communication markets drove Q3 sales increase

* INTERNATIONAL SEGMENTS - International sales boosted by higher energy product sales and JAP Telecom acquisition

* TARIFF IMPACT - Tariffs and LIFO costs affected net income, offset by higher sales margins and lower interest expense

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $178.08

Revenue mln

Q3 EPS $0.53

Q3 Net $2.61

Income mln

Q3 Gross $52.84

Profit mln

Q3 $13.13

Operatin mln

g income

Q3 $2.35

Pretax mln

Profit

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the electrical components & equipment peer group is "buy"

* Wall Street's median 12-month price target for Preformed Line Products Co ( PLPC ) is $200.00, about 14.4% below its October 28 closing price of $228.79

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--HSBC Gets SVB Trade-Secret Lawsuit Trimmed Down
--HSBC Gets SVB Trade-Secret Lawsuit Trimmed Down
Jul 10, 2024
08:35 AM EDT, 07/10/2024 (MT Newswires) -- Price: 43.01, Change: +0.03, Percent Change: +0.07 ...
Virpax Says Non-Narcotic Pain Medication Shows Positive Results in Swine Model Study; Shares Rise
Virpax Says Non-Narcotic Pain Medication Shows Positive Results in Swine Model Study; Shares Rise
Jul 10, 2024
08:34 AM EDT, 07/10/2024 (MT Newswires) -- Virpax Pharmaceuticals ( VRPX ) on Wednesday reported positive results in a swine model pilot study of Probudur, the company's liposomal bupivacaine formulation to provide both immediate and extended pain relief. Probudur was injected into four juvenile domestic pigs at a dose of 30 mg per kilogram and was well-tolerated and demonstrated a...
US regional banks to face increased scrutiny as CRE exposure stifles buybacks
US regional banks to face increased scrutiny as CRE exposure stifles buybacks
Jul 10, 2024
(Reuters) - U.S. regional banks will probably stockpile more rainy-day funds and stay conservative on stock buybacks as losses from commercial real estate (CRE) loans are expected to pressure their earnings, analysts said. As regional lenders prepare to report second-quarter results next week, they continue to face tough scrutiny from investors over potential weakness from CRE and commercial borrowers. Regional...
Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement
Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement
Jul 10, 2024
08:32 AM EDT, 07/10/2024 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Wednesday a phase 2/3 trial has shown that its investigational brain disease treatment, paxalisib, causes clinically significant improvement in overall survival for patients with glioblastoma, a life-threatening brain cancer. Paxalisib showed an approximate 33% improvement in the overall survival of newly diagnosed patients with glioblastoma, compared with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved